While colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining.
A new report that monitored cancer screening rates between 2000 and 2015, using data from the National Health Interview Survey (NHIS), has found that colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 (HP2020) objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining. According to the study, published in the Morbidity and Mortality Weekly Report, race, education, income, and insurance status were significant determinants of disparity among participants.
The authors analyzed NHIS data—a nationally representative sample of the civilian, noninstitutionalized population residing in the United States—which gathers information on the household, each person in the family residing in that household, and a randomly selected sample adult (aged ≥18 years) and child (if present) from each family.
With a focus on cancer screening, adults were asked if they had undergone screening, and those who responded in the affirmative were asked to date their latest screening test. For this study, information on the following tests was gathered:
The authors evaluated screening trends over time using NHIS data from 2000, 2003, 2005, 2008, 2010, 2013, and 2015. Of the 55.2% of adults who responded, mammography use was found stable from 2000 to 2015. In 2015, 71.5% of women, 50 to 74 years old, had a mammogram, which was below the HP2020 target of 81.1%. Racial disparity was evident, with American Indians/Alaska natives reporting the lowest rate of screening (56.7%). Women who born outside the United States and had been living in the country for <10 years had lower rates (53.7%) than those who were born in the United States (72.1%). Further, not surprisingly, uninsured women and those without a usual source of healthcare reported very low rates (35.3% and 32.9%, respectively).
Cervical cancer screening rates saw an overall decline from 2000 to 2015—it touched 83% in 2015, which was 10% below the HP2020 target. Asian women had the lowest rates of screening (75.8%). Lowest screening rates were reported by younger women, between 21- and 30-years old (78.3%), along with women born outside the United States. Insurance trends persisted—only 65.1% among women who lacked a usual source of healthcare and 63.8% among uninsured women.
Colorectal cancer screening increased from 2000 to 2015 but did not achieve the HP2020 target of 70.5%. Screening rates were lowest among American Indians and Alaska natives (48.4%) and Hispanics (47.4%). Screening rates were lower in the 50 to 64 age group (57.9%), compared with the 65 to 75 age group (71.8%). Education and insurance coverage were significant determinants of increased screening rates.
The authors write, “Innovative approaches are needed to reach some racial and ethnic minorities and medically underserved populations to improve the use of cancer screening test use toward the HP2020 targets.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More